Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation dips below year-ago levels
Q3 FY2026 stock-based compensation of $77.2M fell 12.4% year over year, behind the +46.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Stock-based compensation amounted to 6.8% of revenue in FY2025, up 0.7 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.4% toward the trailing-twelve-month pace of +46.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 291.13M USD
- Year-over-year change
- +17.4%
- 4-year CAGR
- +11.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 291.13M | +17.4% |
| FY2024 | 2024-12-31 | 248.05M | +9.3% |
| FY2023 | 2023-12-31 | 226.84M | +2.2% |
| FY2022 | 2022-12-31 | 222M | +17.5% |
| FY2021 | 2021-12-31 | 189.01M | — |
Stock-Based Compensation vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 stock-based compensation of $424.81M is the largest of the 9 companies compared; the peer median is $62.13M.
- Its year-over-year change of +46.2% is the 2nd highest of 8, against a peer median of -9.9%.
- Stock-based compensation amounts to 9.0% of revenue for JAZZ, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $424.81M | +46.2% | +9.5% | 9.0% | |
| LTM Sep 2026 | $235.1M | +4.2% | +8.0% | 6.4% | |
| LTM Jun 2026 | $187.88M | -31.7% | +9.8% | 3.2% | |
| LTM Sep 2026 | $88.18M | +44.6% | +49.9% | 9.8% | |
| LTM Jun 2026 | $71M | — | — | 1.7% | |
| LTM Jun 2026 | $53.27M | +57.8% | — | 18.3% | |
| LTM Jun 2026 | $40.95M | -9.9% | +18.6% | 4.3% | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Sep 2026 | $7.7M | -87.8% | — | 0.6% | |
| Peer median (excluding JAZZ) | $62.13M | -9.9% | +9.8% | 5.3% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (329.67M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| Deferred Income Tax | 69.2M | (292.25M) | (260.22M) | (208.33M) | (444.97M) |
| Stock-Based Compensation | 189.01M | 222M | 226.84M | 248.05M | 291.13M |
| Change in Working Capital | (47.95M) | 9.91M | (204.44M) | (76.72M) | 18.9M |
| Accounts Receivables | (92.74M) | (90.14M) | (51.88M) | (21.12M) | (106.28M) |
| Inventory | (48.86M) | (49.64M) | (13.42M) | (45.54M) | (86.04M) |
| Accounts Payables | 57.02M | (11.23M) | 9.6M | (20.07M) | 39.85M |
| Other Working Capital | 36.62M | 160.91M | (148.74M) | 10.01M | 171.37M |
| Other Non-Cash Items | 345.44M | 926.92M | 276.29M | 212.72M | 1.15B |
| Operating Cash Flow | 778.51M | 1.27B | 1.09B | 1.4B | 1.36B |
| Capital Expenditures | (45.53M) | (498.19M) | (23.96M) | (48.07M) | (209.75M) |
| Acquisitions (Net) | (6.23B) | 53M | 0 | 0 | (858.05M) |
| Purchases of Investments | (26.82M) | (61.04M) | (390.1M) | (1.31B) | (1.83B) |
| Sales of Investments | 1.1B | 60M | 270M | 845M | 1.36B |
| Other Investing Activities | (17.89M) | 0 | (19M) | (10M) | (122.83M) |
| Investing Cash Flow | (5.21B) | (446.23M) | (163.06M) | (508.2M) | (1.51B) |
| Debt Repayment | 3.87B | (582.01M) | (31M) | 374.77M | (781M) |
| Common Stock Issued | 135.26M | 0 | 46.46M | 20.65M | 107.86M |
| Common Stock Repurchased | 0 | (54K) | (269.76M) | (311.43M) | (125.02M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (35.6M) | (45.44M) | (50.95M) | (63.47M) | (75.22M) |
| Financing Cash Flow | 3.97B | (529.49M) | (305.25M) | 20.52M | (873.38M) |
| Effect of Forex Changes | (3.21M) | (6.22M) | 1.14M | (1.68M) | 6.56M |
| Net Change in Cash | (466.32M) | 290.03M | 624.83M | 906.55M | (1.02B) |
| Free Cash Flow | 732.98M | 773.78M | 1.07B | 1.35B | 1.15B |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.